Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Aug 13;67(11):2213–2226. doi: 10.2337/db17-1538

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

PMC Copyright notice

Effect of AMPKα1-DN or AMPKα2-DN microinjection into the VMH on energy balance in rats. A and B: Body weight change (n = 14–17 rats/group). C: Daily food intake (n = 14–17 rats/group). D: BAT temperature (n = 14–17 rats/group). E: Body temperature (n = 14–17 rats/group) of rats fed an SD stereotaxically treated within the VMH with GFP or AMPKα1-DN or AMPKα2-DN adenoviruses and SC with SR59230A (SR SC). F: Body weight change (n = 16–19 rats/group). G: Daily food intake (n = 16–19 rats/group). H: BAT temperature (n = 8 rats/group) of rats fed an HFD stereotaxically treated within the VMH with GFP or AMPKα1-DN adenoviruses. I: Body weight change (n = 7–8 rats/group). J: Food intake (n = 7–8 rats/group). K: BAT temperature (n = 7–8 rats/group) of rats fed an HFD stereotaxically treated within the VMH with null or AMPKα1-DN Lv. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. GFP VMH or null VMH. #P < 0.05, ##P < 0.01, and ###P < 0.001 vs. AMPKα1-DN VMH. Statistical significance was determined by Student t test (when two groups were compared) or ANOVA (when more than two groups were compared) followed by post hoc Bonferroni test. Data are expressed as mean ± SEM.